EUVIMEDEUVIMED entdecken
Crossref

ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways

Keyu Li, Lingli Quan, Fang Huang, Yukun Li, Zhenyu Shen

International Immunopharmacology · 2023-09 · 122 · 110580

DOI: 10.1016/j.intimp.2023.110580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023-09. Verfasst von Keyu Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Affiliated Changsha Hospital of Xiangya School of Medicine Central South University, Changs…. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung adenocarcinoma (LUAD) is a malignant respiratory disease, resulting in a heavy social burden. Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance and tumor immune microenvironment are important directions in the treatment of LUAD. In this study, we confirmed the role of ADAM metallopeptidase domain 12 (ADAM12) in LUAD development and progression. Our bioinformatic analysis was conducted to screen ADAM12 was correlated with EGFR-TKI and immune infiltration in LUAD patients. Our results showed that the transcription and post-transcription level of ADAM12 is significantly increased in tumor samples compared to normal samples, and ADAM12 correlated with poor prognosis in LUAD patients. High level of ADAM12 accelerated the LUAD progression via promoting proliferation, cell cycle, apoptosis escaping, immune escaping, EGFR-TKI resistance, angiogenesis, invasion and migration based on experiment validation in vitro and in vivo, which could be attenuated by ADAM12 knockdown. Further mechanistic studies suggested that the PI3K/Akt/mTOR and RAS signaling pathways were activated after ADAM12 knockdown. Therefore, ADAM12 might be validated as a possible molecular therapy target and prognostic marker for patients with LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungHumansProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesErbB ReceptorsDrug Resistance, NeoplasmCell Line, TumorSignal TransductionTOR Serine-Threonine KinasesCell ProliferationTumor MicroenvironmentADAM12 Protein

Stichwörter der Autor:innen

ADAM12Bioinformatic analysisEGFR-TKI resistanceImmune microenvironmentLung adenocarcinoma

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesErbB ReceptorsTOR Serine-Threonine KinasesEGFR protein, humanADAM12 protein, humanADAM12 Protein

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The Affiliated Changsha Hospital of Xiangya School of Medicine Central South University, Changsha 410008, China.
  • Department of Pulmonary and Critical Care Medicine 1, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Central South University, Zhuzhou 412000, China.
  • Department of General Medicine, The Affiliated Changsha Hospital of Xiangya School of Medicine Central South University, Changsha 410008, China.
  • Department of Assisted Reproductive Centre, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Central South University, Zhuzhou 412000, China. Electronic address: Yukun_li@foxmail.com.
  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Hunan University of Medicine, Huaihua 418000, China. Electronic address: ZhenYuShen0701@126.com.

Zitieren

APA

Li, K., Quan, L., Huang, F., Li, Y., & Shen, Z. (2023). ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways. International Immunopharmacology, 122, 110580. https://doi.org/10.1016/j.intimp.2023.110580

Vancouver

Li K, Quan L, Huang F, Li Y, Shen Z. ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways. International Immunopharmacology. 2023;122:110580. doi:10.1016/j.intimp.2023.110580

BibTeX
@article{Li2023,
  author = {Li, Keyu and Quan, Lingli and Huang, Fang and Li, Yukun and Shen, Zhenyu},
  title = {ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways},
  journal = {International Immunopharmacology},
  year = {2023},
  volume = {122},
  pages = {110580},
  doi = {10.1016/j.intimp.2023.110580}
}
Kostenlos starten →